At a Glance
| Parameter | Recommendation |
|---|---|
| Starting dose | 0.5–1.5 mg nightly |
| Escalation step | +0.5 mg every 7–14 days |
| Typical target | 3.0–4.5 mg |
| Timing | 9–11 pm (empirical optimum) |
| Minimum trial period | 8–12 weeks at target dose |
| Compounding required | Yes — commercial 50 mg tablets are not appropriate |
| Most common titration side effect | Vivid dreams, light insomnia in weeks 1–3 |
| Who should not titrate without specialist review | Active opioid use, pregnancy, severe hepatic impairment |
Low-dose naltrexone (LDN) sits in a therapeutic window far below its FDA-approved opioid-antagonist dose of 50 mg. At 1.5–4.5 mg, the brief receptor blockade triggers a compensatory up-regulation of endogenous opioids and an anti-inflammatory shift in microglial and immune-cell signalling. The clinical rationale is described in our overview of low-dose naltrexone. What that article does not detail is the practical choreography of titration — how to actually start, escalate, plateau, and troubleshoot — which is what patients and prescribers ask about most. This guide fills that gap.
Why Titration Matters with LDN
Naltrexone at any dose is a full opioid antagonist. At low doses, the blockade lasts only 4–6 hours, but during that window the body experiences a transient reduction in endogenous opioid tone. In sensitised individuals — those with fibromyalgia, chronic fatigue, or a history of opioid use — this rebound can cause vivid dreams, sleep fragmentation, or mild irritability in the first weeks.
Starting at the full therapeutic target (4.5 mg) circumvents none of this; it simply delivers it all at once. A graduated approach lets the opioid-receptor system adapt, the patient build confidence in tolerability, and the prescriber identify the minimum effective dose — which for a meaningful minority is 2–3 mg, not 4.5 mg.
Research on naltrexone’s tolerability profile confirms that adverse-event rates drop substantially when titration extends over four or more weeks rather than jumping directly to target dose (Younger et al., 2013).
The Standard Titration Schedule
Week 1–2: Foundation Dose (0.5–1.5 mg)
The first decision is the opening dose. I use three strata:
- 0.5 mg for patients who are highly sensitive (a history of drug reactions, active MCAS, or severe fibromyalgia with central sensitisation)
- 1.0 mg for most adults starting de novo
- 1.5 mg for those who have previously tolerated LDN or who have no significant sensitisation history
Timing: take the capsule at bedtime, ideally between 9 pm and 11 pm. This aligns the receptor blockade with the natural nocturnal opioid peak (approximately 2–3 am), maximising the rebound signal during sleep.
What to expect: Some patients notice nothing. Others report slightly more vivid dreams within the first few nights — this is the most reliable early sign that the medication is pharmacologically active. It generally resolves within 5–10 days.
Week 3–4: First Escalation (2.0–2.5 mg)
If the foundation dose has been tolerated without persistent sleep disruption, increase by 0.5 mg. Maintain this dose for one to two weeks before the next step.
Common pattern: The vivid-dream phenomenon, if it occurred initially, may briefly resurface with each escalation and then resolve again. This is expected and not a reason to pause unless it causes functional daytime impairment.
Week 5–6: Approach the Target (3.0 mg)
3.0 mg is the most commonly reported effective dose in the published fibromyalgia and Crohn’s disease trials and in my clinical experience. A meaningful subset of patients stabilise here and never need to go higher.
After two weeks at 3.0 mg, conduct a brief review:
- Has sleep normalised?
- Has the patient noticed any early symptom changes (fatigue, pain, mood, cognitive clarity)?
- Any GI changes (nausea, loose stools)?
If tolerability is excellent and the clinical response is partial or absent, continue escalation.
Week 7–10: Titrate to 3.5–4.5 mg
Increase in 0.5 mg steps every one to two weeks. Most protocols cap at 4.5 mg; evidence beyond this dose is limited and clinical benefit rarely improves.
Plateau decision: If a patient improves substantially at 3.5 mg, hold there. The goal is the minimum dose producing a sustained response — not the maximum tolerated dose.
When to Pause or Slow the Titration
Persistent Sleep Disruption
If insomnia or vivid dreams persist beyond 10–14 days at a given dose, do not escalate. Options:
- Shift timing earlier (8 pm instead of 10 pm)
- Split the dose: take half in the morning, half at night (evidence is weaker, but some patients report better tolerance)
- Hold at the current dose for a further 2 weeks before attempting another step
Mood Changes or Anxiety
A small percentage of patients — particularly those with a history of anxiety or mood disorders — experience heightened anxiety in the first two weeks. This often relates to the opioid rebound effect. A slower opening dose (0.5 mg) and explicit reassurance about the transient nature of this effect is usually sufficient.
Nausea
Mild nausea occurs in roughly 10% of first-time users. Taking LDN with a light snack rather than on an empty stomach resolves this in most cases.
Titration in Specific Patient Groups
Autoimmune Conditions (Hashimoto’s, MS, Crohn’s, Lupus)
Standard titration applies. For Hashimoto’s thyroiditis in particular — covered in depth in our LDN for Hashimoto’s article — thyroid antibody monitoring at baseline and at week 12 is prudent, as some patients experience a significant antibody reduction requiring TSH re-evaluation and possible levothyroxine dose adjustment.
Fibromyalgia and Central Sensitisation
These patients are disproportionately represented among those who need the slower 0.5 mg start. The supra-sensitivity of central pain pathways can amplify early rebound-related sleep disturbances. A four-week foundation phase at 0.5–1.0 mg before the first escalation is a reasonable precaution. For the evidence base in this population, see our LDN for fibromyalgia article.
Long COVID and CFS/ME
Post-viral patients frequently have profound autonomic sensitivity and disrupted sleep architecture independently of LDN. Starting at 0.5 mg and extending each step to 14 days rather than 7 reduces the likelihood of confusing LDN side effects with underlying post-viral symptoms. Our LDN for long COVID protocol addresses this population in detail.
Patients Over 65
Renal clearance of naltrexone and its active metabolite 6-beta-naltrexol declines modestly with age. A 0.5 mg start and 14-day inter-step intervals are appropriate; some older patients find their effective dose is 2–3 mg rather than 4.5 mg.
What to Monitor During Titration
| Timepoint | Assessment |
|---|---|
| Baseline | LFTs (hepatic function), renal panel, full blood count |
| Week 4 | Tolerability check — sleep, mood, GI, energy |
| Week 8 | Repeat LFTs if hepatic history; patient-reported outcome measures |
| Week 12–16 | First formal efficacy review at target dose |
| Annually | LFTs, disease-specific biomarkers (e.g., thyroid antibodies for Hashimoto’s) |
LDN carries a theoretical hepatotoxic risk at standard naltrexone doses (50 mg), but published safety data at low doses show no clinically significant liver enzyme elevation. Nonetheless, baseline LFTs are standard practice and are reassuring for patient confidence.
Compounding Considerations
Commercial naltrexone tablets (50 mg) cannot be cut reliably to LDN doses; dosing inaccuracy at the microgram level matters when the therapeutic window is 0.5–4.5 mg. Compounding pharmacies prepare LDN in several forms:
- Immediate-release oral capsules — the standard. Aqueous-based or cornstarch filler. Avoid calcium carbonate filler if possible, as it may reduce absorption.
- Liquid suspension — useful for very low starting doses (0.5 mg) and precise titration in paediatric or highly sensitive patients
- Topical cream — limited pharmacokinetic data; not recommended as a first-line formulation when oral is tolerated
Ensure the compounding pharmacy avoids fillers with opioid-receptor activity (there is no standard filler with such activity, but contaminants in low-quality compounding facilities have been implicated in variable response).
Frequently Asked Questions
Can I take LDN in the morning?
Yes, though most evidence and clinical experience is with evening dosing. Morning dosing is sometimes used when sleep disturbance is persistent and unresponsive to timing adjustments. Response rates appear similar, but the pharmacodynamic rationale for evening dosing — aligning blockade with the nocturnal opioid peak — is stronger.
What if I miss a dose?
Skip the missed dose entirely; do not double up. LDN’s mechanism is based on a brief, consistent daily blockade; occasional missed doses do not negate the treatment effect.
How long before I see a clinical response?
Expect 8–12 weeks at the target dose for a meaningful signal. Inflammatory biomarkers (CRP, ESR, cytokine panels) may shift before symptomatic improvement. Manage patient expectations accordingly.
Can LDN be taken with SSRIs, SNRIs, or other medications?
LDN has no significant pharmacokinetic interactions with SSRIs or SNRIs. It is contraindicated with full-dose opioid analgesics and should be used with caution alongside tramadol and high-dose codeine preparations. The interaction profile is otherwise favourable compared with many immunomodulators.
Related Articles
- Low-Dose Naltrexone: Mechanism, Evidence, and Clinical Uses
- LDN for Hashimoto’s Thyroiditis
- LDN for Fibromyalgia
- LDN for Long COVID
- LDN for Multiple Sclerosis
References
- Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. doi:10.1007/s10067-014-2517-2
- Cree BAC, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010;68(2):145–150. doi:10.1002/ana.22006
- Smith JP, Field D, Bingaman SI, et al. Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn’s disease: a pilot study. J Clin Gastroenterol. 2013;47(4):339–345.
- Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538.
- Agrawal YP. Low dose naltrexone therapy in multiple sclerosis. Med Hypotheses. 2005;64(4):721–724.
- Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s disease, and other chronic pain disorders. Pharmacotherapy. 2018;38(3):382–389.
- Raknes G, Simonsen P, Smabrekke L. The effect of low-dose naltrexone on medication in inflammatory bowel disease: a quasi experimental before-and-after prescription database study. J Crohns Colitis. 2017;11(4):449–455.
